Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Acelyrin Stock

Q: Can you buy Acelyrin stock?

You can no longer buy Acelyrinstock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

acelyrin.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $558MM

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Learn more about Acelyrin IPO

Enterprise Value

Access valuation and stock price for companies like Acelyrin before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Acelyrin stock FAQs

Can you buy Acelyrin stock?

You can no longer buy Acelyrin stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Acelyrin stock?

To invest in a private company like Acelyrin through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Acelyrin stock?

You can no longer sell stock of Acelyrin on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Acelyrin stock?

If you hold private company shares of Acelyrin - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Acelyrin stock on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Acelyrin a public company?

No, Acelyrin is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Acelyrin’s stock price?

The stock price of Acelyrin is $5.97 as of 1/18/24.

What is Acelyrin’s stock ticker symbol?

The ticker symbol of Acelyrin is SLRN.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Acelyrin investors also invested in these private companies

Cowen Group

AlphaSense, Escient Pharmaceuticals, Acelyrin

Marshall Wace

Accelerant, Acelyrin, Asher Biotherapeutics, Lycia Therapeutics, Attovia

Matrix Partners

Flock Safety, Sila Nanotechnologies, Lightmatter, Quora, Luma AI, Side, Apollo Graph, Flex, Mashgin, Razorpay

Decheng Capital

Aardvark Therapeutics, Mammoth Biosciences, Cellares, Nalu, Hummingbird Bioscience, Nalu Medical, Acelyrin

Westlake Village BioPartners

ArsenalBio, Acelyrin, Star Therapeutics, 3T Biosciences

OrbiMed Healthcare Fund Management

Acelyrin

Samsara Biocapital

Attralus, Alumis, Delfi Diagnostics, FogPharma, Spyglass Ophthalmics, Obsidian Therapeutics, RayzeBio, Acelyrin, Alamar Biosciences, Mineralys

venBio

Intercom, Attralus, Alumis, FogPharma, RayzeBio, Acelyrin, Attovia

RTW Investments

Beta Bionics, BioAge, Santa Ana Bio, Obsidian Therapeutics, Acelyrin, Lycia Therapeutics, Apogee Therapeutics, Mineralys

Surveyor

Attralus, Aardvark Therapeutics, Quanta Therapeutics, Scorpion Therapeutics, Obsidian Therapeutics, Acelyrin, Boundless Bio, Avenzo

Tybourne Capital Management

Acelyrin

Team

Management Team

Shao-Lee Lin, MD, PhD

Chief Executive Officer

Robert F. Carey

President

Paul Peloso

Chief Medical Officer

Melanie Gloria

Chief Operating Officer

Gil Labrucherie

Chief Financial Officer

Ron Oyston

Senior Vice President, Human Resources

Marc Kubasak

Vice President, Program Lead & Regulatory Affairs

Brian Wiens

Vice President, Biostatistics and Data Sciences

Terry Bevirt

Vice President, Alliance Management, Clinical & Corporate Quality

Katherine To

Vice President - Clinical Operations

Suzy Buckhalter

Senior Director, Finance & Accounting

Tyler Marciniak

Head of Investor Relations and Communications

Shawn Eisnberg

Vice President, Technical Operations

Board Members

Sean Harper

Kin Insurance

Alan Colowick

Sofinnova Investments

Beth Seidenberg

Westlake Village BioPartners

Dan Becker

Access Biotechnology

Richard Gaster

venBio Partners

The Wall Street Journal 09/16/2022

Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials

Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.